We are live on ! Find out more
GM

Gilfoyle Management Portfolio holdings

AUM $25K
This Fund
S&P 500
This Quarter Est. Return
+15.92%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$19.4K
AUM Growth
+$11.9K
Cap. Flow
+$11.1K
Cap. Flow %
57.22%
Top 10 Hldgs %
100%
Holding
5
New
2
Increased
3
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$5.67K
2
TSLA icon
Tesla
TSLA
+$2K
3
ARKK icon
ARK Innovation ETF
ARKK
+$1.47K
4
IVV icon
iShares Core S&P 500 ETF
IVV
+$1.26K
5
QQQ icon
Invesco QQQ Trust
QQQ
+$673

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 25%
2 Consumer Discretionary 12.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.73B
$4.84K 25%
+100
New +$5.67K
IVV icon
2
iShares Core S&P 500 ETF
IVV
$878B
$4.5K 23.25%
10
+3
+43% +$1.26K
ARKK icon
3
ARK Innovation ETF
ARKK
$5.66B
$4.29K 22.16%
100
+37
+59% +$1.47K
QQQ icon
4
Invesco QQQ Trust
QQQ
$453B
$3.33K 17.21%
9
+2
+29% +$673
TSLA icon
5
Tesla
TSLA
$1.23T
$2.4K 12.38%
+10
New +$2K

Similar funds

KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return
ALBM
Alcentra Ltd (BNY Mellon) London, United Kingdom $566K AUM 51.56% 1-Year Est. Return
RIA
RP Investment Advisors Toronto, Ontario, Canada $900K AUM 17.98% 1-Year Est. Return
MVPI
Maven Ventures Partners II Palo Alto, California $958K AUM 41.74% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TMC
TVL Management Corporation Menlo Park, California $1.84M AUM 0.1% 1-Year Est. Return
TAM
Trikon Asset Management Hong Kong $1.84M AUM 172.11% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Gilfoyle Management's Q2 2023 Portfolio in Review

As of Q2 2023, Gilfoyle Management held 5 positions worth $19.4K, up 158% from $7.5K the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Gilfoyle Management deployed $11.1K of net new capital in Q2 2023, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was CRISPR Therapeutics: 100 shares worth $4.84K.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, followed by Consumer Discretionary.

  • Gilfoyle Management's largest Q2 2023 buy was CRISPR Therapeutics: 100 shares worth $4.84K.
  • Gilfoyle Management added most to ARK Innovation ETF in Q2 2023, an estimated $1.47K increase.
  • Gilfoyle Management's ten largest holdings make up 100% of its $19.4K portfolio in Q2 2023.
  • Gilfoyle Management opened 2 new positions and closed 0 in Q2 2023.
  • Gilfoyle Management's portfolio value rose 158% quarter-over-quarter to $19.4K.

Based on Gilfoyle Management's 13F filing for Q2 2023, filed 30 Jun 2023.